STAT

NOVEMBER 13, 2023

PHILADELPHIA – Novo Nordisk, which has dominated the diabetes and obesity markets with its blockbuster drugs Ozempic and Wegovy, now also wants to be a major player in heart disease. It’s also developing several treatments specific to heart disease and is acquiring a medication for high blood pressure.

Diabetes 345

Diabetes Drug Development 345

STAT

FEBRUARY 26, 2024

Type 2 diabetes is the most common – it’s long been linked to obesity, and the latest GLP-1 treatments like Wegovy and Zepbound were initially developed as diabetes drugs. But behind diabetes, the next most common disease under investigation for obesity candidates is MASH.

Diabetes 357

Diabetes Compounding Drug Development 357

STAT

AUGUST 14, 2024

It’s also the latest attempt to deal with one of the biggest challenges in drug development: What should a company do when it wins big? But inventing a mega-blockbuster — in this case novel drugs that treat obesity and diabetes — brings its own set of issues. Victory is hardly defeat.

Diabetes 355

Diabetes Drug Development 355

STAT

SEPTEMBER 5, 2024

Nearly two decades ago, a small company called Amylin Pharmaceuticals saw that its first commercial product, a diabetes treatment targeting receptors of the amylin hormone, led to weight loss in early clinical trials. The company ultimately didn’t pursue an indication in weight loss. Continue to STAT+ to read the full story…

Diabetes 332

Diabetes Drug Development 332

STAT

OCTOBER 17, 2023

Her team had failed to wrestle a gut hormone called GLP-1 into a new kind of drug for diabetes. Thomsen got right to the point. Management was giving them one more shot. And by them, he meant her. “You need to figure out what to do with GLP-1,” he said. “And it has to be now.”

Diabetes 351

Diabetes Drug Development 351

STAT

OCTOBER 24, 2023

But when it comes to what is arguably the hottest space in drug development today — controlling weight and diabetes for millions of people worldwide — the brainy innovators from Kendall Square have missed out on the booming market, at least so far.

Diabetes 248

Diabetes Drug Development 248

STAT

JULY 17, 2024

after four weeks in patients with obesity who did not have diabetes.   The company said its once-daily pill, called CT-996, led to a placebo-adjusted average weight loss of 6.1%

Diabetes 325

Diabetes Drug Development 325

STAT

DECEMBER 11, 2023

And before the end of the month, Vertex will share results from a mid-stage trial in people with diabetes who have chronic nerve pain. The company will announce data early next year from Phase 3 studies testing the molecule’s effectiveness at treating post-surgical pain.

Diabetes 353

Diabetes Drug Development 353

STAT

JUNE 23, 2023

The full   results,  published Friday in the New England Journal of Medicine, were presented here to a packed conference room at the American Diabetes Association conference. The mid-stage results for orforglipron match the estimates of 14-15% weight loss that Lilly gave in an investor call late last year.

Diabetes 259

Diabetes Drug Development 259

STAT

OCTOBER 17, 2024

billion deal in which Novo Nordisk’s parent foundation would acquire Catalent, a leading contract drug manufacturer, over concerns the acquisition will harm competition and reduce patient access to popular diabetes and weight loss medicines.

Diabetes 259

Diabetes Packaging Drug Pricing Drug Development 259

STAT

JUNE 27, 2023

But Eli Lilly has been following close behind with new treatments, and after dropping result after result from successful trials at the American Diabetes Association conference here this past weekend, the Indianapolis-based drugmaker looks to be gaining an edge over its Danish competitor in the race to supply obesity drugs.

Diabetes 238

Diabetes Drug Development 238

STAT

MAY 24, 2024

Also, the agency’s advisers debate Guardant’s colon cancer liquid biopsy test, and we see new data showing Ozempic’s efficacy in preventing death in diabetes and chronic kidney disease patients. Read the rest…

Diabetes 239

Diabetes Drug Pricing Drug Development 239

STAT

JUNE 20, 2024

With the immense demand for GLP-1-based drugs and recurring shortages of the branded treatments, a wide variety of businesses have popped up to offer their own versions of what they claim are GLP-1 drugs. No other company has bid on the contract — to supply 14 million pens for the next three years, at about $2 per pen. The

Diabetes 266

Diabetes Compounding Drug Pricing Drug Development 266

STAT

APRIL 12, 2024

Enjoy, and see you soon… Western drug makers are talking to alternative suppliers in response to draft U.S. legislation seeking to restrict an important Chinese drug developer and manufacturer over national security concerns , The Financial Times explains. But be safe. The Biosecure Act would prohibit U.S.

Drug Development 226

Drug Development Diabetes Drug Pricing 226

STAT

JUNE 24, 2024

On top of today’s Alnylam news, we have Congress gearing up to vote on Medicare coverage for multi-cancer screenings and obesity drug coverage. Also, updates on Vertex’s type 1 diabetes cell therapy, and a push for phage therapy. Read the rest…

Diabetes 220

Diabetes Drug Pricing Drug Development 220

Pharmaceutical Technology

OCTOBER 25, 2022

BioMed X has entered a research partnership with Sanofi to leverage artificial intelligence (AI) for drug development. This team will focus on creating a versatile computational platform that can precisely forecast the first-in-class drug candidates’ efficacy in virtual patient groups.

Drug Development 98

Drug Development Diabetes Immunization Immunity 98

European Pharmaceutical Review

DECEMBER 1, 2023

During CPHI Barcelona, EPR Editor Caroline Peachey asked Anil Kane, Global Head of Technical & Scientific Affairs, Pharma Services, at Thermo Fisher Scientific about the dynamic landscape of pharmaceutical drug development. What are the trends affecting drug development today?

Drug Development 98

Drug Development Dosage Diabetes Process Improvement 98

STAT

JUNE 26, 2023

Among 98 patients with nonalcoholic fatty liver disease, those on the highest dose tested of the drug, retatrutide, experienced an 86% decrease in liver fat over 48 weeks, with most of the reduction occurring early on in treatment, according to data presented here at the American Diabetes Association conference Monday.

Diabetes 250

Diabetes Drug Development 250

Express Pharma

DECEMBER 2, 2024

The company’s Phase III product Rybelsus, already FDA approved for cardiovascular risk factors and type 2 diabetes, is being positioned for a label expansion to include obesity. Novo Nordisk is leading the pack with four separate products, two apiece in Phase III and Phase II.

Labelling 126

Labelling Diabetes Drug Development 126

pharmaphorum

AUGUST 25, 2022

Obesity, diabetes, and genetics are the primary drivers, and COVID is about to make this exponentially worse. Dozens of companies are working at various stages of drug development. The post Fatty liver disease: With little early detection, more challenging drug development appeared first on. About the Author.

Drug Development 98

Drug Development Diabetes 98

STAT

OCTOBER 27, 2023

The plan is to increase investment in its drug-development pipeline and cut costs, and the split could take place as early as the fourth quarter of 2024. The panel committee reviewed non-clinical, clinical, and post-marketing data of the drugs, and said that no updates to their prescribing information was required at the time.

Diabetes 260

Diabetes Drug Development 260

BioPharma Dive

MAY 29, 2024

An acquisition of EyeBio will hand Merck a treatment for diabetic macular edema and age-related macular degeneration that’s ready for pivotal testing.

Drug Development 73

Drug Development Diabetes 73

STAT

JANUARY 12, 2024

Food and Drug Administration did not find evidence that GLP-1 drugs like Ozempic and Wegovy cause suicidal thoughts or actions , STAT notes. Novartis backed away from its pursuit of Cytokinetics, putting a damper on the prospects of a deal for the promising heart-drug developer , The Wall Street Journal reports.

Diabetes 259

Diabetes Drug Development 259

STAT

MAY 22, 2023

A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus. Novo Nordisk said it plans to submit oral semaglutide for U.S. approvals later this year. Continue to STAT+ to read the full story…

Diabetes 246

Diabetes Drug Development 246

Pharmaceutical Technology

FEBRUARY 24, 2023

(LAI-287 + semaglutide) is under clinical development by Novo Nordisk and currently in Phase III for Type 2 Diabetes. According to GlobalData, Phase III drugs for Type 2 Diabetes have a 53% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration.

Diabetes 72

Diabetes Drug Development 72

STAT

JULY 17, 2024

Patients on insulin fear the GLP-1 gold rush is leaving them behind As Novo Nordisk and Eli Lilly invest billions to scale up manufacturing capacity for their highly profitable GLP-1 drugs, diabetes patients around the world are suddenly facing shortages of various insulin products. Read the rest…

Diabetes 186

Diabetes Drug Pricing Drug Development 186

STAT

OCTOBER 25, 2024

Food and Drug Administration maintains its list of drug shortages and which sources it relies on, an issue that affects a growing number of Americans , STAT explains. Earlier this month, the FDA declared an end to the shortage of Lilly’s tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, after almost two years.

Compounding 198

Compounding Compounding Pharmacies Diabetes Drug Development 198

PharmaShots

APRIL 10, 2023

Shots: With an incurable nature and hefty medication costs, diabetes mellitus remains a global health concern and the seventh leading cause of death across the world. Diabetes, aka diabetes mellitus is a condition that arises when the pancreas fails to produce enough insulin or the cells of the body do not respond to the insulin produced.

Diabetes 40

Diabetes Biosimilars Pharmaceutical Companies Pharmaceutical Companies 40

PharmExec

OCTOBER 31, 2023

Collaboration aims to expand space research in studies of heart disease and diabetes.

Drug Development 52

Drug Development Diabetes 52

PharmExec

OCTOBER 31, 2023

Collaboration aims to expand space research in studies of heart disease and diabetes.

Drug Development 52

Drug Development Diabetes 52

Express Pharma

JULY 1, 2024

Momna Ali, Healthcare Analyst at GlobalData, states, “Amylyx’s acquisition of avexitide marks its entry into the drug development field for metabolic diseases, a departure from its prior focus on neurodegenerative diseases. This shift in strategy comes after Relyvrio’s disappointing efficacy results from the drug’s confirmatory trial.

Labelling 104

Labelling Diabetes Drug Development 104

The Digital Apothecary

MAY 13, 2017

As a pharmacy educator, I love the history of drug development for instance, and in every discussion, I have with students, whether in the classroom or small groups, I like to frame our current understanding of what we are doing based on what we used to do. Take for example Type I Diabetes (sometimes called Juvenile Diabetes).

Diabetes 130

Diabetes Vaccines Pharmaceutical Companies Pharmaceutical Companies 130

pharmaphorum

JANUARY 17, 2022

The drug, developed by Incyte and licenced to Lilly, is also used to treat rheumatoid arthritis. US-based Eli Lilly’s baricitinib (Olumiant), a Janus kinase inhibitor, and GlaxoSmithKline and Vir Biotechnology’s sotrovimab, a monoclonal antibody, were recommended in new WHO guidelines, published in the British Medical Journal. .

Hospitals 116

Hospitals Diabetes Immunization Immunity 116

European Pharmaceutical Review

NOVEMBER 9, 2023

Following her presentation on age-related disease at BioFuture 2023, Executive Vice President of Drug Development for MyMD Pharmaceuticals ® , Jenna Brager, shares with EPR why the company’s next-generation tumour necrosis factor (TNF)-alpha inhibitor has potential in inflammatory and autoimmune disorders.

Drug Development 115

Drug Development Immunity Immunization Pharmaceutical Companies 115

Express Pharma

APRIL 17, 2024

Biopharmaceutical companies are regaining interest in metabolic dysfunction-associated steatohepatitis (MASH) innovator drug development. MASH innovator drugs witnessed over $2.5

Drug Development 95

Drug Development Diabetes 95

European Pharmaceutical Review

JULY 25, 2023

Rising demand for affordable and accessible drugs in regions like Asia-Pacific, Latin America, and Africa can offer potential for manufacturers in this sector to become established in these markets and work on their drug development. This opportunity can lead to higher production and revenue, the research reported.

Compounding 97

Compounding Generic Medicine Drug Development Diabetes 97

European Pharmaceutical Review

APRIL 24, 2023

Positive results from the long-term follow-up of a Phase II study of small molecule inhibitor UBX1325 in patients with diabetic macular edema (DME) have been announced. The long-term data from the clinical trial demonstrate “a remarkable result,” according to Anirvan Ghosh, PhD, Chief Executive Officer of UNITY.

Diabetes 97

Diabetes Drug Development 97